Access Statistics for Tomas Philipson

Author contact details at EconPapers.

Working Paper File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Aging and the Growth of Long-Term Care 1 2 2 2 3 7 9 9
Aging and the Growth of Long-Term Care 1 5 18 198 16 38 101 1,055
An Empirical Examination of Information Barriers to Trade in Insurance 6 7 50 304 14 50 236 1,910
An Empirical Examination of Information Barriers to Trade inInsurance 0 0 0 0 1 4 34 868
Antitrust and the Not-For-Profit Sector 1 4 18 253 10 27 79 763
Antitrust in the Not-For-Profit Sector 1 2 16 93 11 19 71 290
Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process 1 5 16 71 7 20 67 345
Assessing the Safety and Efficacy of the FDA: The Case of the Prescription Drug User Fee Acts 1 1 3 64 5 15 33 180
Consumption vs. Production of Insurance 0 0 2 103 3 5 17 717
Data MArkets and OPtimal Sample Size Determination 0 0 0 0 4 10 42 2,696
Death, Tetanus and Aerobics: The Evaluation of Disease-Specific Health Interventions 1 1 5 43 3 9 39 346
Death, Tetanus, and Aerobics: The Evaluation of Disease-Specific Health Interventions 0 0 2 2 0 1 6 63
Disease Complementarities and the Evaluation of Public Health Interventions 1 1 9 105 2 4 19 834
Disease Eradication: Private vs. Public Vaccination 0 0 0 0 3 8 26 380
Economic Epidemiology and Infectious Diseases 1 16 113 606 11 53 295 1,871
Endogenous Cost-Effectiveness Analysis in Health Care Technology Adoption 6 10 19 19 9 23 51 51
Estimating the Extent of Trade Under Incomplete Information: The Case of HIV 0 0 0 0 0 0 6 99
External Treatment Effects and Program Implementation Bias 1 1 7 48 6 16 70 314
External Treatment Effects and Program Implementation Bias 0 0 0 0 3 3 5 5
Health Care, Technological Change, and Altruistic Consumption Externalities 1 2 4 30 2 18 50 172
Health Investment Complementarities under Competing Risks 0 0 5 155 1 5 21 991
Integrated Insurance Design in the Presence of Multiple Medical Technologies 1 1 4 12 5 9 33 75
Intellectual Property & External Consumption Effects: Generalizations from Pharmaceutical Markets 2 4 7 140 2 10 31 431
Intellectual Property and Marketing 3 6 13 65 5 10 43 211
Is Health Care Technology Over-Approved? A Meta-Analysis of Revealed Preference 0 0 0 0 1 2 5 150
Is the Food and Drug Administration Safe and Effective? 2 5 17 54 9 17 57 155
Is the Obesity Epidemic a Public Health Problem? A Decade of Research on the Economics of Obesity 9 26 104 183 27 74 269 429
Merit Motives and Government Intervention: Public Finance in Reverse 0 0 9 190 2 9 38 765
Merit Motives and Government Intervention: Public Finance in Reverse 0 1 6 99 12 26 84 789
Mortality Contingent Claims, Health Care, and Social Insurance 0 0 0 0 3 6 26 1,035
Mortality Contingent Claims, Health Care, and Social Insurance 0 1 5 126 1 5 29 465
Nonprofit Production 0 0 0 0 0 3 14 142
Nonprofit Production and Competition 0 1 10 258 3 11 48 1,100
Observational Agency and Supply-Side Econometrics 0 0 0 24 3 4 14 336
Pricing and R&D with Related Margins 0 0 0 0 2 4 22 493
Rational Epidemics and their Public Control 0 0 0 0 6 14 59 387
Self-Interested Treatment Evaluation in Experiments 0 0 0 0 1 2 9 87
Surplus Appropriation from R&D and Health Care Technology Assessment Procedures 1 4 15 85 9 22 103 390
Surplus Appropriation from R&D and Health Care Technology Assessment Procedures 4 6 17 51 8 17 51 199
The Dual Effects of Intellectual Property Regulations: Within- and Between- Patent Competition in the US Pharmaceuticals Industry 0 1 13 244 0 11 68 653
The Dual Effects of Intellectual Property Regulations: Within- and Between-Patent Competition in the US 0 0 5 6 1 4 19 21
The Future of Old-Age Longevity: Competitive Pricing of Morality Contingent Claims 0 0 0 0 0 2 24 932
The Future of Old-Age Longevity: Competitive Pricing of Mortality Contingent Claims 1 3 11 61 2 6 39 282
The Growth of Obesity and Technological Change: A Theoretical and Empirical Examination 2 10 34 318 9 29 95 911
The Growth of Obesity and Technological Change: A Theoretical and Empirical Examination 1 7 28 29 8 20 74 75
The Long-Run Growth in Obesity as a Function of Technological Change 0 3 21 416 4 10 75 1,765
The Long-Run Growth in Obesity as a Function of Technological Change 1 4 8 8 5 9 14 14
The Private Demand for Information and the Effects of Public Testing Programs: The Case of HIV 0 0 0 0 0 2 9 377
The Quantity and Quality of Life and the Evolution of World Inequality 7 12 44 596 19 39 152 1,622
The Rise in Old Age Longevity and the Market for Long-Term Care 0 0 0 0 2 8 31 648
The Rise in Old Age Longevity and the Market for Long-Term Care 2 3 19 192 11 23 98 1,527
The Value of Life Near its End and Terminal Care 4 11 48 159 11 27 142 343
The Value of Life Near its End and Terminal Care 4 9 40 111 9 19 80 190
The Value of Life in General Equilibrium 1 7 24 55 2 15 81 140
Who Benefits from New Medical Technologies? Estimates of Consumer and Producer Surpluses for HIV/AIDS Drugs 2 8 16 89 11 26 80 283
Will the AIDS Epidemic be Self-Limiting? Evidence on the Responsiveness of the Demand for Condoms to the Prevalence of AIDS 2 3 5 5 2 3 5 5
Will the AIDS Epidemic be Self-Limiting? Evidence on the Responsiveness of the Demand for Condoms to the Prevalence of AIDS 0 0 0 1 0 2 15 193
Total Working Papers 72 193 812 5,673 309 835 3,313 31,579

Journal Article File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
A Theoretical and Empirical Investigation of the Effects of Public Health Subsidies for STD Testing 1 3 17 91 1 4 30 317
An Empirical Examination of Information Barriers to Trade in Insurance 0 0 16 155 2 11 52 550
An empirical examination of the implications of assortative matching on the incidence of HIV 1 1 3 22 1 1 7 40
Antitrust in the Not-for-Profit Sector 1 6 21 21 16 34 68 68
Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process 0 0 1 10 0 0 12 78
Commentary 0 0 0 0 0 1 3 9
Commentary 0 0 1 2 1 1 2 7
Commentary 0 0 0 0 1 1 2 6
Commentary 0 0 0 0 1 1 1 5
Commentary 0 1 1 2 1 2 2 8
Commentary 0 0 0 1 2 2 4 11
Cost-benefit analysis of the FDA: The case of the prescription drug user fee acts 0 2 25 34 3 10 87 134
Cost-effectiveness analysis and innovation 3 6 30 37 5 15 78 95
Data Markets and the Production of Surveys 1 1 4 9 1 1 6 37
Data Markets, Missing Data, and Incentive Pay 0 0 0 0 0 0 5 112
Disease Eradication: Private versus Public Vaccination 3 9 35 151 9 20 87 406
Dynamic information release 0 0 0 0 0 0 0 0
Equilibrium and Efficiency in an Organized Vote Market 0 0 0 0 0 3 15 127
Integrated Insurance Design in the Presence of Multiple Medical Technologies 1 1 1 1 2 3 6 52
Is the Food And Drug Administration Safe And Effective? 0 0 0 0 11 17 55 61
Is the Obesity Epidemic a Public Health Problem? A Review of Zoltan J. Acs and Alan Lyles's Obesity, Business and Public Policy 0 0 0 0 4 12 23 23
Labor Supply and Weight 0 0 3 3 0 0 5 5
Longevity Complementarities under Competing Risks 2 3 20 83 4 7 48 234
Managed Care and the Quality of Health Care: A Misguided Debate? 0 0 0 0 4 5 29 134
Measurement errors: A principal investigator-agent approach 0 0 1 14 0 0 6 48
Multiple-output agency incentives in data production: experimental evidence 0 0 1 3 0 0 1 18
Old-Age Longevity and Mortality-Contingent Claims 2 2 15 135 4 5 32 490
Pricing and R&D When Consumption Affects Longevity 0 0 0 0 1 2 10 112
Public Financing and the Market for Long-Term Care 0 0 5 13 0 0 11 40
Public Spending on AIDS Education: An Economic Analysis 0 0 0 0 1 2 18 187
Rational Epidemics and Their Public Control 0 0 0 1 3 10 73 283
Social Welfare and Measurement of Segregation 0 1 7 30 1 4 13 57
Subject Evaluation in Social Experiments 0 0 0 0 4 6 33 223
The Economic Epidemiology of Crime 0 0 0 1 14 27 114 733
The Quantity and Quality of Life and the Evolution of World Inequality 8 21 75 331 20 45 196 1,016
The Rise in Old-Age Longevity and the Market for Long-Term Care 0 2 12 40 0 4 32 127
The evaluation of new health care technology: The labor economics of statistics 1 2 8 49 8 12 54 244
The institute of medicine report on the FDA: where is the science? 0 0 3 15 0 2 19 83
The nonprofit sector and industry performance 2 5 18 61 3 9 60 200
The welfare loss of disease and the theory of taxation 1 1 2 22 2 2 9 49
The world-wide growth in obesity: an economic research agenda 0 0 0 3 13 28 130 334
Welfare-Enhancing Technological Change and the Growth of Obesity 3 5 21 64 3 9 38 146
Who Benefits from New Medical Technologies? Estimates of Consumer and Producer Surpluses for HIV/AIDS Drugs 0 0 2 3 0 2 10 21
Total Journal Articles 30 72 348 1,407 146 320 1,486 6,930

Chapter File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process 0 0 0 0 0 2 6 6
Asymmetric Information and the Not-for-Profit Sector Does Its Output Sell a a Premium? 2 4 4 4 3 7 7 7
Economic epidemiology and infectious diseases 8 30 96 214 21 73 253 579
Medical Care Output and Productivity in the Nonprofit Sector 0 0 0 0 0 0 2 2
Public Financing and the Market for Long-Term Care 0 1 1 1 1 3 3 3
Theories of Firm Behavior in the Nonprofit Sector. A Synthesis and Empirical Evaluation 1 2 10 10 1 3 13 13
Total Chapters 11 37 111 229 26 88 284 610

logo

LogEc Home

Top Working Papers
Top Journal Articles
Top Books
Top Chapters
Top Software Items

Top Authors

Top Working Paper series and Journals

About LogEc

Authors with papers registered in the RePEc Author Service.

Register yourself as an author or register more papers in the RePEc Author Service.

Authors with no registered papers

RePEc
LogEc provides access and usage for services based on the RePEc data set.

Örebro UniversityLogEc is hosted by the Swedish Business School at Örebro University.

Questions or comments? Please see our explanation of how the statistics are collected or e-mail

Statistics updated 2009-11-04